Search
Cisplatin Treatment Options in Canada
A collection of 326 research studies where Cisplatin is the interventional treatment. These studies are located in the Canada . Cisplatin is used for conditions such as Head and Neck Cancer, Lung Cancer and Non-small Cell Lung Cancer.
313 - 324 of 326
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer
Terminated
This study will summarize the safety of patients receiving figitumumab combined with etoposide and cisplatin (or carboplatin) vs. patients receiving etoposide and cisplatin (or carboplatin) alone as first line treatment for extensive stage disease Small Cell Lung Cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/18/2013
Locations: Pfizer Investigational Site, Washington, District of Columbia +50 locations
Conditions: Small Cell Lung Carcinoma
Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether receiving cisplatin with raltitrexed is more effective than cisplatin alone for malignant mesothelioma.
PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin with or without raltitrexed in treating patients who have malignant mesothelioma of the pleura.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2012
Locations: U.Z. Gasthuisberg, Leuven, Not set +25 locations
Conditions: Malignant Mesothelioma
S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. Vaccines may make the body build an immune response to kill tumor cells. Combining chemotherapy and radiation therapy with vaccine therapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy and radiation therapy with vaccine therapy in treating patients who hav... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2012
Locations: MBCCOP - Gulf Coast, Mobile, Alabama +99 locations
Conditions: Lung Cancer
S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer
Withdrawn
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether cisplatin is more effective when combined with paclitaxel or gemcitabine in treating cervical cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin combined with paclitaxel to that of cisplatin combined with gemcitabine in treating women who have recurrent, persi... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
06/11/2012
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +105 locations
Conditions: Cervical Cancer
A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer
Completed
This study is designed to determine whether the combination of low dose cisplatin and strontium-89 shows clinical promise for the symptomatic treatment of bone metastases in hormone refractory prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
01/18/2012
Locations: Tom Baker Cancer Centre, Calgary, Alberta +1 locations
Conditions: Hormone Refractory Prostate Cancer, Bone Metastases
Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining tirapazamine with cisplatin in treating patients who have recurrent ovarian epithelial or primary peritoneal cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
01/07/2012
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +53 locations
Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
CRP on Radiobiological and Clinical Studies on Viral-Induced Cancer's Response to Radiotherapy
Completed
The purpose of this trial is to study clinical effects of two/four high dose rate (HDR) brachytherapy applications and teletherapy with or without weekly cisplatin in cervix cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/13/2011
Locations: University of Vienna; Department of Radiotherapy and Radiobiology, Vienna, Not set +10 locations
Conditions: Cervix Cancer
S0216, Combination Chemotherapy and RT in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and radiation therapy in treating patients with stage III or stage IV head and neck cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2011
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +94 locations
Conditions: Head and Neck Cancer
A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors
Completed
This study will assess the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with pemetrexed, pemetrexed and cisplatin or pemetrexed and carboplatin in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/07/2011
Locations: Pfizer Investigational Site, Aurora, Colorado +2 locations
Conditions: Neoplasms
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
Unknown
RATIONALE: Imaging procedures, such as fludeoxyglucose F18 positron emission tomography (\^18FDG-PET), may improve the ability to detect disease progression and help doctors predict a patient's response to treatment and plan more effective treatment.
PURPOSE: This phase II trial is studying how well \^18FDG-PET imaging works in detecting disease progression and determining response to treatment in patients who are undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2011
Locations: Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama +48 locations
Conditions: Lung Cancer
Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Completed
The purpose of the study is to compare time to progression and overall survival after treatment with Taxotere plus cisplatin versus cisplatin plus 5-FU (PF treatment group) in the first line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/19/2011
Locations: sanofi-aventis US, Bridgewater, New Jersey +19 locations
Conditions: Head and Neck Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis
CPG 7909 Injection in Non-Small Cell Lung Cancer
Completed
Eligible patients will be randomized in a ratio of 2:1 to receive either chemotherapy (a taxane and a platinum compound) plus CPG 7909 Injection or chemotherapy alone. Protocol therapy will be administered until disease progression or intolerable toxicity. CpG 7909 Injection will be administered subcutaneously, on Weeks 2 and 3 of each three-week cycle (days 8 and 15) and chemotherapy will be administered on Week 1 (Day 1). Patients will undergo complete disease evaluation at the end of every ot... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2009
Locations: Office of Ronald Yanagihara, Gilroy, California +23 locations
Conditions: Carcinoma, Non-Small Cell Lung
313 - 324 of 326